



FINAL MEETING

December 16th, 2021

VIRTUAL MEETING

Thursday, 16th December 2021 (Starting time: 11.00 Berlin - 10.00 UK - 12.00 Israel)

WELCOME

11.00-11.05

Welcome

Hans-Dieter Volk - Charité - Universitätsmedizin Berlin, Germany (5 min)

DESCRIPTION OF WORK I

11.05-11.45

WP3 Clinical Phase III Study

Nitsan Halevy - Pluristem, Israel (40 min)

11.45-12.30

WP2: Molecular and functional signature of the PLX-PAD cell product

Cell product characterization and Functional Assays

Guido Moll, Karsten Jürchott, Stephan Schlickeiser, Naima Souidi - Charité - Universitätsmedizin Berlin, Germany (30 min)

Update Proteomic analysis of PLX-derived extracellular vesicles

Martin Wolf, Dirk Strunk - Paracelsus Medizinische Privatuniversität, Austria (15 min)

12.30-12.40

Break

DESCRIPTION OF WORK II

12.40-13.10

WP4: Biomarkers in the follow-up of the study patients and WP5: Exploratory molecular, immunological, and functional biomarker and mechanistical side studies

Update biomarker analyses

Guido Moll - Charité - Universitätsmedizin Berlin, Germany (20 min)

Update Proangiogenic Factors in vivo/ Response pattern of EPC and immune cells to PLX-EV

Martin Wolf, Dirk Strunk - Paracelsus Medizinische Privatuniversität, Austria (10 min)

13.10-13.25

WP6: Project management and coordination

Gabriella Dessoie - Innovation Acta, Italy (15 min)

MEETING CLOSURE

13.25-13.30

Conclusions

Hans-Dieter Volk - Charité - Universitätsmedizin Berlin, Germany (5 min)

13.30-14.00

EAB / EPMT MEETING FOR SELECTED PARTICIPANTS

EAB: Stefan Anker, Sebastian Sethe, Giuseppe Rosano

EPMT: Hans-Dieter Volk, Racheli Ofir, Gabriella Dessoie, Nitsan Halevy

Invited guests: Guido Moll

EAB + EPMT Meeting



This project is supported through Societal Challenges (Health, demographic change and well-being) of the European Community's H2020. Grant agreement number 733006.

Organization and
Graphic project by:
Inn·Acta